Versartis Inc (NASDAQ:VSAR) insider Colin Hislop sold 35,000 shares of the company’s stock in a transaction on Tuesday, April 4th. The shares were sold at an average price of $21.20, for a total transaction of $742,000.00. Following the sale, the insider now owns 59,500 shares of the company’s stock, valued at approximately $1,261,400. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of Versartis Inc (NASDAQ:VSAR) traded up 0.381% during trading on Friday, reaching $19.775. 174,775 shares of the company were exchanged. The stock’s 50-day moving average is $20.40 and its 200-day moving average is $15.59. The firm’s market cap is $693.03 million. Versartis Inc has a 52-week low of $7.05 and a 52-week high of $24.00.
Versartis (NASDAQ:VSAR) last announced its quarterly earnings results on Tuesday, February 21st. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by $0.02. During the same quarter in the previous year, the firm earned ($0.69) EPS. Equities research analysts predict that Versartis Inc will post ($2.51) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Versartis Inc (VSAR) Insider Colin Hislop Sells 35,000 Shares” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/04/21/colin-hislop-sells-35000-shares-of-versartis-inc-vsar-stock-updated.html.
Several brokerages have commented on VSAR. Piper Jaffray Companies upped their target price on shares of Versartis from $22.00 to $26.00 and gave the company an “overweight” rating in a research report on Tuesday, April 4th. Barclays PLC began coverage on shares of Versartis in a research report on Thursday, March 9th. They set an “overweight” rating and a $28.00 target price for the company. Canaccord Genuity reiterated a “buy” rating and set a $28.00 target price on shares of Versartis in a research report on Wednesday, February 22nd. Finally, Zacks Investment Research raised shares of Versartis from a “hold” rating to a “buy” rating and set a $17.00 price target for the company in a report on Friday, January 6th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Versartis currently has a consensus rating of “Buy” and a consensus price target of $23.86.
Hedge funds have recently made changes to their positions in the stock. Woodstock Corp bought a new stake in shares of Versartis during the first quarter worth about $589,000. Highbridge Capital Management LLC increased its stake in shares of Versartis by 20.3% in the fourth quarter. Highbridge Capital Management LLC now owns 29,396 shares of the biopharmaceutical company’s stock worth $438,000 after buying an additional 4,970 shares during the last quarter. Teachers Advisors LLC increased its stake in shares of Versartis by 15.0% in the fourth quarter. Teachers Advisors LLC now owns 50,368 shares of the biopharmaceutical company’s stock worth $750,000 after buying an additional 6,573 shares during the last quarter. Perceptive Advisors LLC bought a new stake in shares of Versartis during the fourth quarter worth about $61,889,000. Finally, Metropolitan Life Insurance Co. NY increased its stake in shares of Versartis by 22.5% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 23,257 shares of the biopharmaceutical company’s stock worth $347,000 after buying an additional 4,270 shares during the last quarter. 70.15% of the stock is currently owned by hedge funds and other institutional investors.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc and related companies with MarketBeat.com's FREE daily email newsletter.